The Exelixis story began in 1994 when our prominent team of founding scientists set out to use model system genetics as a means to systematize drug discovery. This vision ultimately resulted in our flagship commercial product, CABOMETYX® (cabozantinib), and set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve. We’ve redefined the role of small molecule therapeutics – alone and in combination with immune checkpoint inhibitors – working with clinicians to try to set new standards of care for multiple cancer types. These efforts, combined with our development and commercialization partnerships across the globe, extend our reach and impact to more patients.